Breakthrough Biomaterial Heals Damaged Tissue From the Inside Out — Just By Injecting It Into the Bloodstream

<p>Imagine a material that you inject into the bloodstream and it <em>finds</em> the damaged tissue in your body, calms the inflammation, and kickstarts healing from the inside out. It sounds like science fiction — but researchers at the University of California San Diego have made it real.</p><h2>How It Works</h2><p>The breakthrough biomaterial is based on a <strong>hydrogel made from the natural scaffolding of cardiac muscle tissue</strong> (known as the extracellular matrix). When injected intravenously, the material travels through the bloodstream, naturally accumulates at sites of tissue damage, and creates a supportive structure that encourages cell growth and repair.</p><p><em>"This biomaterial allows for treating damaged tissue from the inside out,"</em> said <strong>Professor Karen Christman</strong>, the UC San Diego bioengineering lead. <em>"It's a new approach to regenerative engineering."</em></p><h2>Proven in Heart Attack Models</h2><p>Heart attacks remain one of the most serious medical emergencies, with an estimated <strong>785,000 new cases each year</strong> in the US alone. When blood flow is blocked, cardiac tissue dies and is replaced by scar tissue that can't contract — gradually weakening the heart.</p><p>Currently, there is <strong>no established therapy</strong> that directly repairs heart tissue after an attack. The new biomaterial successfully treated heart attack damage in both rodent and large animal models, reducing inflammation and promoting tissue repair.</p><h2>Beyond the Heart</h2><p>The researchers also provided proof of concept that the same biomaterial could help with:</p><ul><li><strong>Traumatic brain injury</strong></li><li><strong>Pulmonary arterial hypertension</strong></li></ul><p>The key advantage over previous approaches is that it can be <strong>delivered via a simple IV infusion</strong> rather than requiring invasive catheter procedures directly into the heart.</p><h2>Path to Patients</h2><p>An earlier version of the technology (delivered directly via catheter) already completed a <strong>successful Phase 1 human clinical trial</strong> in 2019, demonstrating safety and feasibility. The intravenous version could open the door to much wider, easier use.</p><p>Dr Ryan R. Reeves, a UC San Diego interventional cardiologist, said: <em>"As someone who treats patients with coronary artery disease and congestive heart failure daily, I would love to have another therapy to improve patient outcomes and reduce debilitating symptoms."</em></p><p><em>Sources: University of California San Diego, ScienceDaily, Nature Biomedical Engineering (May 5, 2026)</em></p>